Debbie Robbrecht
Erasmus University Rotterdam
36 Papers
23 Citations
Debbie Robbrecht is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 17 publications.
Chat about Author
Papers
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
Irene Brana,Geoffrey I. Shapiro,Melissa Lynne Johnson,Helena Alexandra Yu,Debbie Robbrecht,Daniel Shao-Weng Tan,Lillian L. Siu,Hironobu Minami,Neeltje Steeghs,Thomas Hengelage,Eugene Tan,Kelly Biette,Kun Xu,Susan Moody,Maria Jove +14 more
TL;DR: TNO155 is a selective, allosteric, oral inhibitor of SHP2 that transduces signals from activated receptor tyrosine kinases to downstream pathways including MAPK, and Methods: CTNO155X2.3005.
51
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors : Results from a Phase I/II Clinical Trial
Reetta Virtakoivu,Jenna H. Rannikko,Miro Viitala,Felix Vaura,Akira Takeda,Tapio Lönnberg,Jussi Koivunen,Panu Jaakkola,Annika Pasanen,Shishir Shetty,Maja J.A. de Jonge,Debbie Robbrecht,Yuk Ting Ma,Tanja Skyttä,Anna Minchom,Sirpa Jalkanen,Matti K Karvonen,J. Mandelin,Petri Bono,Maija Hollmén +19 more
TL;DR: In this article, the authors analyzed the mode of action of a humanized IgG4 anti-Clever-1 antibody, FP-1305 (bexmarilimab), both in vitro and in patients with heavily pretreated metastatic cancer (n = 30) participating in part 1 (dose-finding) of a phase I/II open-label trial (NCT03733990).
34
Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)
I. Melero,E. Castanon Alvarez,Morten Mau-Sørensen,Ulrik Lassen,Martijn P. Lolkema,Debbie Robbrecht,Carlos Gomez-Roca,J. Martin-Liberal,Josep Tabernero,Willeke Ros,Sharif Uddin Ahmed,N. Isambert,H. Piper Lepoutre,Christophe Boetsch,Jehad Charo,Stefan Evers,Volker Teichgräber,Jan H.M. Schellens +17 more
18
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
Hanneke van der Wijngaart,L.R. Hoes,J. Maxime van Berge Henegouwen,Daphne L. van der Velden,L.J. Zeverijn,Paul Roepman,Erik van Werkhoven,Wendy W.J. de Leng,Anne M.L. Jansen,Niven Mehra,Debbie Robbrecht,Mariette Labots,Derk Jan A. de Groot,Ann Hoeben,Paul Hamberg,Hans Gelderblom,Emile E. Voest,Henk M.W. Verheul +17 more
TL;DR: In this article, the efficacy of PARP inhibitor (PARPi) in patients with tumors with BRCA1/2 mutations, regardless of histologic tumor type, was evaluated using a Simon-like two-stage model.
17
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
Debbie Robbrecht,Juanita Lopez,Emiliano Calvo,Xiaomin He,Hirai Hiroshi,Nital Soni,Natalie Cook,Afshin Dowlati,Angelica Fasolo,Victor Moreno,Ferry A.L.M. Eskens,Johann S. de Bono +11 more
TL;DR: TAS-119 has a favourable and remarkably distinct safety profile from other AurA inhibitors, and target inhibition in paired skin biopsies was shown.
14